

*AMENDMENTS TO THE CLAIMS*

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Currently Amended) A method for the therapeutic treatment of a carcinoma in a mammal wherein (i) the mammal comprises a mutated fibroblast growth factor receptor-4 (FGFR-4) protein, and (ii) the mutated FGFR-4 protein comprises the amino acid sequence of SEQ ID NO: 9 except that glycine at position 388 of SEQ ID NO: 9 has been substituted with arginine, which method comprises administering to the mammal an effective amount of at least one inhibitor of the mutated FGFR-4 selected from the group consisting of a low molecular weight substance, an anti-FGFR-4 antibody, and a kinase inactive FGFR-4, ~~wherein~~ whereby the carcinoma in the mammal is treated.

2. (Canceled)

3. (Previously Presented) The method of claim 1, wherein said carcinoma is breast cancer, squamous cell carcinoma, glioblastoma, neuroblastoma, or uterine cancer.

4. (Previously Presented) The method of claim 1, wherein said inhibitor is a kinase-inactive FGFR-4.

5.-12. (Canceled)

13. (Previously Presented) The method of claim 1, wherein the mutated FGFR-4 protein is encoded by a FGFR-4 gene comprising a germ line mutation.

14.-29. (Canceled)

30. (New) The method of claim 4, wherein said carcinoma is breast cancer, squamous cell carcinoma, glioblastoma, neuroblastoma, or uterine cancer.

31. (New) The method of claim 30, wherein the mutated FGFR-4 protein is encoded by a FGFR-4 gene comprising a germ line mutation.

32. (New) The method of claim 4, wherein the mutated FGFR-4 protein is encoded by a FGFR-4 gene comprising a germ line mutation.

33. (New) A method for the therapeutic treatment of a carcinoma in a mammal wherein (i) the mammal comprises a mutated fibroblast growth factor receptor-4 (FGFR-4) protein, and (ii) the mutated FGFR-4 protein comprises the amino acid sequence of SEQ ID NO: 9 except that glycine at position 388 of SEQ ID NO: 9 has been substituted with arginine, which method comprises administering to the mammal an effective amount of an anti-FGFR-4 antibody, whereby the carcinoma in the mammal is treated.

34. (New) The method of claim 33, wherein said carcinoma is breast cancer, squamous cell carcinoma, glioblastoma, neuroblastoma, or uterine cancer.

35. (New) The method of claim 34, wherein the mutated FGFR-4 protein is encoded by a FGFR-4 gene comprising a germ line mutation.

36. (New) The method of claim 33, wherein the mutated FGFR-4 protein is encoded by a FGFR-4 gene comprising a germ line mutation.